Showing results (791-800 of 881) with videos related to

Sort By:
Pageof 89
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting TreatmentsEthel D Weld, Jacqueline Astemborski, Gregory D Kirk, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirinS C Gordon, E M Yoshida, E J Lawitz, et al.
Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.
JAMA|July 20, 2014
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfectionMark S Sulkowski, Susanna Naggie, Jacob Lalezari, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
The Medical Journal of Australia|May 30, 2021
Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare StandardsEva Segelov, Christine Carrington, Sanchia Aranda, et al.
Neuron|September 7, 2022
LINE-1 activation in the cerebellum drives ataxiaTakehiro Takahashi, Milan Stoiljkovic, Eric Song, et al.
Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Pageof 89